Phase II single-arm study of durvalumab and tremelimumab with concurrent radiotherapy in patients with mismatch repair-proficient metastatic colorectal cancer

  • Neil H. Segal
  • , Andrea Cercek
  • , Geoffrey Ku
  • , Abraham J. Wu
  • , Andreas Rimner
  • , Danny N. Khalil
  • , Diane Reidy-Lagunes
  • , John Cuaron
  • , T. Jonathan Yang
  • , Martin R. Weiser
  • , Paul B. Romesser
  • , Zsofia K. Stadler
  • , Anna M. Varghese
  • , Karuna Ganesh
  • , Rona Yaeger
  • , Louise C. Connell
  • , David Faleck
  • , Ghassan K. Abou-Alfa
  • , Kathleen C. Mcauliffe
  • , Pamela Vaiskauskas
    • Mark L. Solter, Martinique Ogle, Matthew J. Adamow, Aliya Holland, Pallavi Vedantam, Phillip Wong, Taha Merghoub, Efsevia Vakiani, Travis J. Hollmann, Krishna Juluru, Joanne F. Chou, Marinela Capanu, Joseph Erinjeri, Stephen Solomon, Yoshiya Yamada, Nancy Kemeny, Christopher H. Crane, Leonard B. Saltz

Research output: Contribution to journal › Article › peer-review

76 Scopus citations

Fingerprint

Dive into the research topics of 'Phase II single-arm study of durvalumab and tremelimumab with concurrent radiotherapy in patients with mismatch repair-proficient metastatic colorectal cancer'. Together they form a unique fingerprint.
Sort by

Keyphrases

Medicine and Dentistry

Immunology and Microbiology

Pharmacology, Toxicology and Pharmaceutical Science